Login / Signup

Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.

Shih-Chieh ShaoKai-Cheng ChangSwu-Jane LinShang-Hung ChangMing-Jui HungYuk-Ying ChanEdward Chia-Cheng Lai
Published in: Cardiovascular diabetology (2021)
In this study, history of established ASCVD was associated with different hHF risks among SGLT2 inhibitors. For T2D patients without ASCVD, dapagliflozin may offer a more favorable hHF reduction effect, compared to empagliflozin, in clinical practice. Future prospective studies should be conducted to validate our findings.
Keyphrases